CLINICAL TRIALS AND OBSERVATIONS Efficacy of deferasirox in reducing and preventing cardiac iron overload in -thalassemia
نویسندگان
چکیده
1Royal Brompton Hospital, London, United Kingdom; 2University College London, London, United Kingdom; 3Universitá di Milano, Policlinico Foundation, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Milan, Italy; 4Cairo University, Cairo, Egypt; 5University Malaya Medical Centre, Lembah Pantai, Kuala Lumpur, Malaysia; 6Ege University Medical Faculty, Izmir, Turkey; 7Ain Shams University, Cairo, Egypt; 8Chulalongkorn University and King Chulalongkorn Memorial Hospital, Bangkok, Thailand; 9Prince of Wales Hospital, Chinese University of Hong Kong, Hong Kong; 10Hospital Kuala Lumpur, Kuala Lumpur, Malaysia; 11Faculty of Medicine Siriraj Hospital, Department of Pediatrics, Division of Haematology-Oncology, Bangkoknoi, Bangkok, Thailand; 12First Department of Pediatrics, University of Athens, Athens, Greece; 13Novartis Pharmaceuticals, East Hanover, NJ; 14Novartis Pharma, Basel, Switzerland; and 15American University of Beirut, Beirut, Lebanon
منابع مشابه
CLINICAL TRIALS AND OBSERVATIONS Effect of transfusional iron intake on response to chelation therapy in -thalassemia major
The success of chelation therapy in controlling iron overload in patients with thalassemia major is highly variable and may partly depend on the rate of transfusional iron loading. Using data from the 1-year phase III study of deferasirox, including volumes of transfused red blood cells and changes in liver iron concentration (LIC) in 541 patients, the effect of iron loading on achieving neutra...
متن کاملPlenary Paper CLINICAL TRIALS AND OBSERVATIONS A 1-year randomized controlled trial of deferasirox vs deferoxamine for myocardial iron removal in b-thalassemia major (CORDELIA)
A 1-year randomized controlled trial of deferasirox vs deferoxamine for myocardial iron removal in b-thalassemia major (CORDELIA) Dudley J. Pennell, John B. Porter, Antonio Piga, Yongrong Lai, Amal El-Beshlawy, Khawla M. Belhoul, Mohsen Elalfy, Akif Yesilipek, Yurdanur Kilinç, Tomasz Lawniczek, Dany Habr, Marianne Weisskopf, Yiyun Zhang, and Yesim Aydinok, on behalf of the CORDELIA study invest...
متن کاملCLINICAL TRIALS AND OBSERVATIONS Deferasirox reduces iron overload significantly in nontransfusion-dependent thalassemia: 1-year results from a prospective, randomized, double-blind, placebo-controlled study
1American University of Beirut, Beirut, Lebanon; 2University College London, London, United Kingdom; 3Department of Pediatrics and Internal Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand; 4First Department of Pediatrics, University of Athens, Athens, Greece; 5Ramathibodi Hospital, Mahidol University, Bangkok, Thailand; 6Chulalongkorn University and King Chulalongkorn Memorial...
متن کاملCLINICAL TRIALS AND OBSERVATIONS Stroke With Transfusions Changing to Hydroxyurea (SWiTCH)
Stroke is a devastating complication of sickle cell anemia (SCA) with high recurrence if untreated. Chronic transfusions reduce recurrent strokes but have associated morbidities including iron overload. Stroke With Transfusions Changing to Hydroxyurea (SWiTCH) was a multicenter phase 3 randomized trial comparing standard treatment (transfusions/chelation) to alternative treatment (hydroxyurea/p...
متن کاملCLINICAL TRIALS AND OBSERVATIONS Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: efficacy and safety during 5 years’ follow-up
1Universitá di Milano, Ca Granda Foundation Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Milan, Italy; 2Centre National de Greffe de Moelle Osseuse, Bab Saadoun, Tunis, Tunisia; 3Istanbul University Medical Faculty, Istanbul, Turkey; 4Suleyman Demirel University Medical Faculty, Isparta, Turkey; 5Ospedale Civico, G Di Cristina e Benfratelli, Palermo, Italy; 6Children’s Hospital ...
متن کامل